11.03.15 to 11.04.15
Rio de Janeiro, Brazil

On October 13, Mike McQuestion, Director of Sabin’s Sustainable Immunization Financing (SIF) program, spoke to officials in the parliament in Tbilisi, Georgia, lauding the country’s impressive performance on immunization and calling for other countries to follow its example.

During the month of October, END7 student supporters are celebrating NTD Success Stories — spreading the exciting news that many countries around the world have already made incredible progress towards the control and elimination of some NTDs. In recent weeks, there have been many new successes to celebrate.
Dr. Sazaly has been involved with dengue research for over 20 years and has also maintained strong research interest in emerging infectious diseases. His interest in dengue, in particular, is rooted in its knowledge gaps: “it is a fascinating disease needing a lot more research to take on.” In an interview with DVI, Dr. Sazaly shares more on his views of dengue prevention and control and needs in the dengue research field.

New Partnership with India Aims to Build Vaccine Manufacturing Network for Hookworm, Other Diseases

WASHINGTON, D.C., BANGALORE, AMSTERDAM — October 14, 2015 — The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) today announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs). The European Union, through its EuropeAid program, recently awarded a five-year grant of €333,000 to AIGHD to establish this EU-India partnership.

The initial research for the Ebola vaccine was published in 2003, where it sat for more than a decade waiting for a vaccine manufacturer to invest in licensing and development. Only after the 2014 outbreak began did the U.S.